-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On March 29, Sino Biopharmaceutical announced that the Group's self-developed Class 1 anti-tumor innovative drug "FHND5071" was approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of advanced solid tumors
FHND5071 was developed by the research team of the group using computer-aided drug design and traditional drug design methods, and through the structure-activity analysis of medicinal chemistry, structure optimization, and in vitro and in vivo biological activity and pharmacokinetic (DMPK) screening.